Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Patent
1996-11-12
1998-07-07
Fitzgerald, David L.
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
536 235, 4353201, 435325, 4352523, C12N 1512, C07K 14705
Patent
active
057767343
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This invention relates to a novel heteromultimer and its use in screening pharmaceutically active compounds for modulators of maxi-K channel activity. Such modulators are useful in treating asthma, pregnant human myometrium, cerebral ischemia and in conditions where stimulation of neurotransmitter release is desired such as Alzheimer's disease and stimulation of damaged nerves.
The present invention relates to the combined use of both the .alpha. and .beta. subunit of a mammalian calcium-activated potassium channel originally identified and separated from bovine tracheal smooth muscle, which confers pharmacological properties to the .alpha. and .beta. subunit complex similar to that found with the native channel. It further relates to the use of the .alpha.-.beta. heteromultimer in expression systems as assays for agonists or antagonists of calcium-activated potassium channels.
Potassium channel antagonists are useful for a number of physiological disorders in mammals, including humans. Ion channels, including potassium channels, are found in all mammalian cells and are involved in the modulation of various physiological processes and normal cellular homeostasis. Potassium channels generally control the resting membrane potential, and the efflux of potassium ions causes repolarization of the plasma membrane after cell depolarization. Potassium channel antagonists prevent repolarization and cause the cell to stay in the depolarized, excited state.
There are a number of potassium channel subtypes. Physiologically, one important subtype is the maxi-K channel, defined as high-conductance calcium-activated potassium channel, which is present in neuronal tissue and smooth muscle. Intracellular calcium concentration (Ca.sup.2+ i) and membrane potential gate these channels. For example, maxi-K channels are opened to enable efflux of potassium ions by an increase in the intracellular Ca.sup.2+ concentration or by membrane depolarization (change in potential). Elevation of intracellular calcium concentration is required for neurotransmitter release, smooth muscle contraction, proliferation of some cell types and other processes. Modulation of maxi-K channel activity therefore affects cellular processes that depend on influx of calcium through voltage-dependent pathways, such as transmitter release from the nerve terminals and smooth muscle contraction. The screening procedures revealed by the present invention are therefore useful for detecting compounds with utility in the treatment of neurological disorders in which neurotransmitter release is impaired.
A number of marketed drugs function as potassium channel antagonists. The most important of these include the compounds Glyburide, Glipizide and Tolbutamide. These potassium channel antagonists are useful as antidiabetic agents. Potassium channel antagonists are also utilized as Class III antiarrhythmic agents and to treat acute infractions in humans. A number of naturally occurring toxins are known to block potassium channels including apamin, iberiotoxin, charybdotoxin, margatoxin, noxiustoxin, kaliotoxin, dendrotoxin(s), mast cell degranuating (MCD) peptide, and .beta.-bungarotoxin (.beta.-BTX).
Depression is related to a decrease in neurotransmitter release. Current treatments of depression include blockers of neurotransmitter uptake, and inhibitors of enzymes involved in neurotransmitter degradation which act to prolong the lifetime of neurotransmitters.
It is believed that certain diseases such as depression, memory disorders and Alzheimer's disease are the result of an impairment in neurotransmitter release. Potassium channel antagonists may therefore be utilized as cell excitants which should stimulate release of neurotransmitters such as acetylcholine, serotonin and dopamine. Enhanced neurotransmitter release should reverse the symptoms associated with depression and Alzheimer's disease.
The present invention relates to the use of the calcium activated potassium channel .alpha. and .beta. subunits in transient or stable coexpre
REFERENCES:
patent: 4960867 (1990-10-01), Garcia et al.
patent: 5401652 (1995-03-01), Sokol et al.
patent: 5637470 (1997-06-01), Kaczorowski et al.
Garcia-Calvo, M., et al., "Purification and Reconstitution of the High-conductance, Calcium-activated Potassium Channel from Tracheal Smooth Muscle", Chem., vol. 269(1), pp. 676-682, 1994.
Knaus, H.G., et al., "Subunit Composition of the High Conductance Calcium-activated Potassium Channel from Smooth Muscle, a Representative of the mSlo and slowpoke Family of Potassium Channels", J. Biol. Chem., vol. 269(6), pp. 3921-3924, 1994.
Lu, L., et al., "Ca2+-activated K+ Channels from Rabbit Kidney Medullary Thick Ascending Limb Cells Expressed in Xenopus Oocytes", J. Biol. Chem., vol. 265(27), pp. 16190-16205, 1990.
McManus, O.B., et al., "An Activator of Calcium-Dependent Potassium Channels Isolated from a Medicinal Herb", Biochemistry, vol. 32(24), pp. 6128-6133, 1993.
Gianagiacomo, K.M., et al., "Synthetic Charybdotoxin-Iberiotoxin Chimeric Peptides Define Toxin Binding Sites on Calcium-Activated and Voltage-Dependent Potassium Channels", Biochem., vol. 32, pp. 2362-2370, 1993.
Ashcroft, F.M., et al., "Expression of K Channels in Xenopus Laevis Oocytes Injected with Poly(A+) mRNA from the Insulin-secretimg Beta-cell line, HIT T15", Febs Lett., vol. 239, pp. 185-189, 1988.
Knaus, H.G., et al., "Primary Sequence and Immunological Characterization of Beta-Subunit of High Conductance Ca2+-activated K+ Channel from Smooth Muscle", J. Biol. Chem., vol. 269, pp. 17274-17278, 1994.
Folander Kimberly L.
Garcia Maria L.
Kaczorowski Gregory J.
Leonard Reid J.
McManus Owen B.
Camara Valerie J.
Daniel Mark R.
Fitzgerald David L.
Garcia-Rivas J. Antonio
Merck & Co. , Inc.
LandOfFree
DNA encoding the .beta. subunit of a mammalian maxi-K potassium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA encoding the .beta. subunit of a mammalian maxi-K potassium , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding the .beta. subunit of a mammalian maxi-K potassium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1204412